B细胞清除疗法是如何起作用的，又如何能够得到改进？
How does B cell depletion therapy work, and how can it be improved?
作者信息
Clark E A, Ledbetter J A
机构信息
Department of Immunology and National Primate Research Center, Box 357330, University of Washington, Seattle, WA 98195, USA.
出版信息
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv77-80. doi: 10.1136/ard.2005.042507.
Abstract
The past few years have seen a surge of interest in B cell depletion therapy for patients with rheumatoid arthritis. This paper outlines the possible mechanism(s) by which B cell depletion therapy works. It is likely there is more than one mechanism and the relative importance of each mechanism depends on the target cell. These include CD20-induced apoptosis, complement dependent cytotoxicity, antibody dependent cell-mediated cytotoxicity, and selective targeting and depletion of B cell subsets. The implications of these mechanisms in the further improvement of B cell depletion therapy in rheumatoid arthritis and other autoimmune diseases are discussed.
摘要
在过去几年里，针对类风湿性关节炎患者的B细胞清除疗法引发了极大的关注。本文概述了B细胞清除疗法起作用的可能机制。可能存在不止一种机制，且每种机制的相对重要性取决于靶细胞。这些机制包括CD20诱导的细胞凋亡、补体依赖性细胞毒性、抗体依赖性细胞介导的细胞毒性以及B细胞亚群的选择性靶向和清除。本文还讨论了这些机制对进一步改进类风湿性关节炎及其他自身免疫性疾病的B细胞清除疗法的意义。
相似文献
1
How does B cell depletion therapy work, and how can it be improved?B细胞清除疗法是如何起作用的，又如何能够得到改进？
Ann Rheum Dis. 2005 Nov;64 Suppl 4(Suppl 4):iv77-80. doi: 10.1136/ard.2005.042507.
2
B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders.类风湿关节炎及其他自身免疫性疾病中的B淋巴细胞清除疗法。
Biochem Soc Trans. 2002 Aug;30(4):824-8. doi: 10.1042/bst0300824.
3
Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.奥法木单抗作为类风湿关节炎及其他自身免疫性疾病中CD20靶向治疗的前景。 （注：原文中多了一个of，正确句子应该是“Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases.” ）
Immunotherapy. 2016 Sep;8(9):1091-6. doi: 10.2217/imt-2016-0003.
4
B cells as a therapeutic target in autoimmune disease.B细胞作为自身免疫性疾病的治疗靶点。
Arthritis Res Ther. 2003;5(3):131-5. doi: 10.1186/ar751. Epub 2003 Mar 19.
5
Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.类风湿关节炎中活化外周血记忆B细胞的扩增、B细胞清除疗法的影响及反应生物标志物
PLoS One. 2015 Jun 5;10(6):e0128269. doi: 10.1371/journal.pone.0128269. eCollection 2015.
6
B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.利妥昔单抗用于类风湿关节炎的B淋巴细胞清除疗法。
Rheum Dis Clin North Am. 2004 May;30(2):393-403, viii. doi: 10.1016/j.rdc.2004.01.006.
7
B cell therapies for rheumatoid arthritis: beyond B cell depletion.B 细胞治疗类风湿关节炎：超越 B 细胞耗竭。
Rheum Dis Clin North Am. 2010 May;36(2):325-43. doi: 10.1016/j.rdc.2010.02.003.
8
No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice.没有B细胞——就没有活跃的类风湿关节炎？类风湿关节炎中B细胞耗竭的进展——临床实践条件下的重复治疗
Rheumatology (Oxford). 2007 Apr;46(4):563-4. doi: 10.1093/rheumatology/kel424. Epub 2007 Mar 3.
9
Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis.抗肿瘤坏死因子治疗与类风湿关节炎中的 B 细胞。
Arthritis Res Ther. 2009;11(5):128. doi: 10.1186/ar2809. Epub 2009 Oct 6.
10
B-cell depletion in autoimmune diseases. Advances in autoimmunity.自身免疫性疾病中的B细胞耗竭。自身免疫进展。
Autoimmun Rev. 2009 Jun;8(7):585-90. doi: 10.1016/j.autrev.2009.02.003. Epub 2009 Feb 10.
引用本文的文献
1
Body mass index does not affect response of rituximab in patients with rheumatoid arthritis: results from the TURKBİO registry.体质指数并不影响类风湿关节炎患者对利妥昔单抗的应答：来自 TURKBİO 登记研究的结果。
Turk J Med Sci. 2023 Jun 21;53(5):1321-1329. doi: 10.55730/1300-0144.5698. eCollection 2023.
2
Risk of cervical pre-cancer and cancer in women with multiple sclerosis exposed to high efficacy disease modifying therapies.暴露于高效疾病修正疗法的多发性硬化症女性患宫颈癌前病变和癌症的风险。
Front Neurol. 2023 Feb 10;14:1119660. doi: 10.3389/fneur.2023.1119660. eCollection 2023.
3
Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.类风湿关节炎发病机制的最新研究进展：新的治疗策略。
Cells. 2021 Nov 4;10(11):3017. doi: 10.3390/cells10113017.
4
Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside.免疫检查点抑制剂相关性肌炎：从生物学到临床。
Int J Mol Sci. 2020 Apr 26;21(9):3054. doi: 10.3390/ijms21093054.
5
Phenotypic identification of CD19CD5CD1d regulatory B cells that produce interleukin 10 and transforming growth factor β in human peripheral blood.人外周血中产生白细胞介素10和转化生长因子β的CD19⁺CD5⁺CD1d⁺调节性B细胞的表型鉴定
Arch Med Sci. 2019 Sep;15(5):1176-1183. doi: 10.5114/aoms.2018.77772. Epub 2018 Aug 27.
6
A comprehensive review of rituximab therapy in rheumatoid arthritis patients.类风湿关节炎患者利妥昔单抗治疗的全面综述。
Clin Rheumatol. 2019 Nov;38(11):2977-2994. doi: 10.1007/s10067-019-04699-8. Epub 2019 Aug 1.
7
Mature IgD B cells maintain tolerance by promoting regulatory T cell homeostasis.成熟 IgD+B 细胞通过促进调节性 T 细胞的稳态来维持耐受。
Nat Commun. 2019 Jan 14;10(1):190. doi: 10.1038/s41467-018-08122-9.
8
Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.奥扎尼莫德（RPC1063），一种选择性 S1PR1 和 S1PR5 调节剂，可减轻慢性炎症并缓解小鼠系统性红斑狼疮的肾脏病变。
PLoS One. 2018 Apr 2;13(4):e0193236. doi: 10.1371/journal.pone.0193236. eCollection 2018.
9
Management of primary Sjögren's syndrome: recent developments and new classification criteria.原发性干燥综合征的管理：最新进展与新分类标准
Ther Adv Musculoskelet Dis. 2018 Feb;10(2):39-54. doi: 10.1177/1759720X17746319. Epub 2018 Jan 1.
10
miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.miR-125b和miR-532-3p可预测利妥昔单抗介导的淋巴细胞清除在慢性淋巴细胞白血病患者中的疗效。一项法国创新白血病组织研究。
Haematologica. 2017 Apr;102(4):746-754. doi: 10.3324/haematol.2016.153189. Epub 2017 Jan 25.
本文引用的文献
1
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.利妥昔单抗（美罗华，抗CD20单克隆抗体）在非霍奇金淋巴瘤中调节的细胞和分子信号转导途径：对化疗增敏和治疗干预的影响。
Oncogene. 2005 Mar 24;24(13):2121-43. doi: 10.1038/sj.onc.1208349.
2
The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice.在小鼠的抗CD20免疫治疗过程中，腹膜腔为B1细胞和传统B淋巴细胞提供了一个保护性微环境。
J Immunol. 2005 Apr 1;174(7):4389-99. doi: 10.4049/jimmunol.174.7.4389.
3
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy.细胞微环境和循环动力学在B细胞免疫治疗中的重要性。
J Immunol. 2005 Jan 15;174(2):817-26. doi: 10.4049/jimmunol.174.2.817.
4
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.基于肿瘤浸润免疫细胞分子特征预测滤泡性淋巴瘤的生存率
N Engl J Med. 2004 Nov 18;351(21):2159-69. doi: 10.1056/NEJMoa041869.
5
Emerging approaches for the therapy of autoimmune and chronic inflammatory disease.
Curr Opin Immunol. 2004 Dec;16(6):780-6. doi: 10.1016/j.coi.2004.09.005.
6
Prospects for B-cell-targeted therapy in autoimmune disease.自身免疫性疾病中B细胞靶向治疗的前景。
Rheumatology (Oxford). 2005 Feb;44(2):151-6. doi: 10.1093/rheumatology/keh446. Epub 2004 Oct 27.
7
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer.在结肠炎相关癌症的小鼠模型中，IKKβ将炎症与肿瘤发生联系起来。
Cell. 2004 Aug 6;118(3):285-96. doi: 10.1016/j.cell.2004.07.013.
8
From the bench to the bedside: ways to improve rituximab efficacy.从实验室到临床：提高利妥昔单抗疗效的方法。
Blood. 2004 Nov 1;104(9):2635-42. doi: 10.1182/blood-2004-03-1110. Epub 2004 Jun 29.
9
The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.在抗CD20抗体免疫治疗期间，先天性单核吞噬细胞网络通过Fc受体依赖性机制消耗B淋巴细胞。
J Exp Med. 2004 Jun 21;199(12):1659-69. doi: 10.1084/jem.20040119.
10
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis.利妥昔单抗靶向B细胞治疗对类风湿关节炎患者的疗效。
N Engl J Med. 2004 Jun 17;350(25):2572-81. doi: 10.1056/NEJMoa032534.
Zotero 插件